百奥赛图-B(2315.HK)大幅拉升涨超24%，现报35.62港元，有望刷新上市新高价，目前总市值158亿港元。消息上，深交所公告称，港股通标的证券名单调 整，调入百奥赛图-B，12月24日起生效。被调入"港股通"名单，意味着内地投资者可以通过沪深港通机制直接买卖该股票。这通常被视为一项重大利好，主 要通过流动性、估值和知名度三个核心层面带来积极影响。 ...

每经AI快讯，12月24日，截至发稿，百奥赛图-B(02315.HK)涨18.95%。根据深交所的公告，港股通标的 证券名单调整，调入百奥赛图-B，12月24日起生效。 ...

25家公司公布了全年业绩预告，业绩预增公司有19家，占比76.00%。 | 代码 | 简称 | 业绩预告日 | 预计净利润增幅中值 | 最新收盘价 | 今年以来涨跌幅 | 行业 | | --- | --- | --- | --- | --- | --- | --- | | | | 期 | （%） | （元） | （%） | | | 688796 | 百奥赛 图 | 2025.12.09 | 303.57 | 50.86 | -22.71 | 医药生 物 | | 688802 | 沐曦股 份 | 2025.12.16 | 54.22 | 667.60 | -19.56 | 电子 | （文章来源：证券时报网） 证券时报·数据宝统计显示，截至12月24日，已经有25家公司公布了2025年度业绩预告。业绩预告类型 显示，预增公司19家，报喜公司比例为76.00%；业绩预降、预亏公司分别有2家、1家。 业绩预喜公司中，以预计净利润增幅中值统计，共有1家公司净利润增幅超100%；净利润增幅在 50%~100%之间的有1家。具体到个股看，百奥赛图预计净利润增幅最高。公司预计全年实现净利润增 幅中值为303.57%；沐曦股份 ...

Group 1 - The stock of Baiaosaitu-B (02315.HK) surged nearly 20% in early trading, reaching a price of 34.3 HKD, with a trading volume of 22.7351 million HKD [2]

Group 1 - The core point of the article is that 百奥赛图-B (02315.HK) has seen its stock price increase by over 16% following its inclusion in the Hong Kong Stock Connect program, effective from today [1] Group 2 - The inclusion in the Hong Kong Stock Connect is expected to enhance the company's visibility and accessibility to a broader range of investors [1] - The stock price surge reflects positive market sentiment and potential growth opportunities for the company [1] - This development may lead to increased trading volume and liquidity for 百奥赛图-B in the Hong Kong market [1]

国泰海通证券此前指出，百奥赛图是国内领先的临床前CRO及生命技术企业，拥有全球领先的基因编 辑技术平台，模式小鼠资源丰富，通过"千鼠万抗"计划大力发展抗体开发业务，海外业务增长潜力强 劲。 消息面上，上交所、深交所发布公告称，因百奥赛图-B在香港市场价格稳定期结束且相应A股上市满10 个交易日，根据有关规定，港股通标的证券名单发生调整并自2025年12月24日起生效，调入百奥赛图。 百奥赛图-B(02315)早盘大涨近20%，截至发稿，涨19.51%，报34.3港元，成交额2273.51万港元。 ...

Group 1 - The core viewpoint of the article highlights a significant increase in the stock price of Baiaosaitu-B (02315), which surged nearly 20% in early trading, reaching HKD 34.3 with a trading volume of HKD 22.7351 million [1] - The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that Baiaosaitu-B will be added to the Hong Kong Stock Connect eligible securities list effective December 24, 2025, following the end of its price stabilization period in the Hong Kong market and after being listed for 10 trading days in A-shares [1] - Guotai Junan Securities previously noted that Baiaosaitu is a leading preclinical CRO and life technology company in China, possessing a globally advanced gene editing technology platform and abundant resources of model mice, significantly developing its antibody development business through the "Thousand Mice and Ten Thousand Antibodies" initiative, with strong growth potential in overseas markets [1]

Core Viewpoint - The Shenzhen Stock Exchange announced the adjustment of the Hong Kong Stock Connect eligible securities list, specifically including Baidu Biotechnology-B (02315) due to its A-share listing meeting the 10 trading days requirement and the end of its price stabilization period in the Hong Kong market, effective from December 24, 2025 [1]. Group 1 - The adjustment involves Baidu Biotechnology-B being included in the Hong Kong Stock Connect [1][3]. - The decision is based on the company's A-share listing having been active for 10 trading days [1]. - The price stabilization period for Baidu Biotechnology-B in the Hong Kong market has concluded [1].

Group 1 - The Shenzhen Stock Exchange has announced an adjustment to the list of eligible securities for the Hong Kong Stock Connect, with the addition of Baiaosaitu-B (2315.HK), effective from December 24 [1]

每经AI快讯，12月24日，深交所公告称，港股通标的证券名单调整，调入百奥赛图-B(02315)，12月24 日起生效。 ...